

Review Article

Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis

Abolfazl Akbari ⁽¹⁾,^{1,2} Shiva Hadizadeh ⁽¹⁾,^{2,3} and Leida Heidary ⁽¹⁾,^{4,5}

¹Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran ²Research Center for Advanced Technologies in Cardiovascular Medicine, Cardiovascular Research Institute, Tehran University of

Medical Sciences, Tehran, Iran

³Women Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

⁴Laboratory of Medical Genetics, ART and Stem Cell Research Centre (ACECR), Tabriz, Iran

⁵Nahal Infertility Center, Tabriz, Iran

Correspondence should be addressed to Abolfazl Akbari; masteraa1379.ir@gmail.com

Received 16 September 2023; Revised 8 February 2024; Accepted 23 February 2024; Published 18 March 2024

Academic Editor: Emmanuel K Ofori

Copyright © 2024 Abolfazl Akbari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Beyond glycemic control, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been proposed to reduce the risk of cardiovascular events. The aim of the present systematic review and meta-analysis is to demonstrate the effects of GLP-1 RA and SGLT2is on intima-media thickness (IMT). *Methods.* PubMed, EMBASE, Web of Science, SCOPUS, and Google Scholar databases were searched from inception to September 9, 2023. All interventional and observational studies that provided data on the effects of GLP-1 RAs or SGLT2is on IMT were included. Critical appraisal was performed using the Joanna Briggs Institute checklists. IMT changes (preintervention and postintervention) were pooled and meta-analyzed using a random-effects model. Subgroup analyses were based on type of medication (GLP-1 RA: liraglutide and exenatide; SGLT2i: empagliflozin, ipragliflozin, tofogliflozin, and dapagliflozin), randomized clinical trials (RCTs), and diabetic patients. *Results.* The literature search yielded 708 related articles after duplicates were removed. Eighteen studies examined the effects of GLP-1 RA, and eleven examined the effects of SGLT2i. GLP-1 RA and SGLT2i significantly decreased IMT (MD = -0.123, 95% CI (-0.170, -0.076), P < 0.0001, $I^2 = 98\%$ and MD = -0.048, 95% CI (-0.092, -0.004), P = 0.031, $I^2 = 95\%$, respectively). Metaregression showed that IMT change correlated with baseline IMT, whereas it did not correlate with gender, duration of diabetes, and duration of treatment. *Conclusions*. Treatment with GLP-1 RA and SGLT2i can lower IMT in diabetic patients, and GLP-1 RA may be more effective than SGLT2i.

1. Introduction

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and sodium/glucose cotransporter 2 inhibitors (SGLT2is) have been introduced for the treatment of type 2 diabetes mellitus (T2DM). Their promising results in glycemic control and weight loss, as well as their low risk of hypoglycemia, less adverse events, and favourable renocardiovascular effects have made them desirable therapies for the treatment of T2DM and its concomitant diseases and complications [1]. In addition to their putative target, numerous molecular targets for GLP-1s have been identified, justifying their potential for broader medical applications, including autophagy, oxidative stress, platelet function, lipid metabolism, and inflammation [2–9]. GLP-1 RA causes an increase in insulin secretion and a decrease in glucagon levels in response to glucose and delays gastric emptying, thereby suppressing postprandial hyperglycemia and appetite, resulting in a decrease in total energy intake and body weight [10]. SGLT2is act independently of insulin; they

block renal glucose reabsorption mediated by SGLT2 expressed along proximal tubules and cause glucosuria [7].

Carotid intima-media thickness (IMT) is a quick and noninvasive ultrasound marker that indicates the thickness of the two innermost layers of the carotid artery. It is a risk stratification tool used as a surrogate marker for atherosclerosis in numerous studies to assess the risk of cardiovascular events [11–13]. We are interested in comparing the effects of GLP-1 RA and SGLT2i therapies on IMT, which may reflect the cardioprotective effects of these drugs. A direct comparison of the cardioprotective benefits of two second-line therapies in T2DM could help us find a better strategy for glycemic control. However, no systematic comparison has been performed for GLP-1 RA or SGLT2i therapies in terms of their effect on IMT. Therefore, we performed a comprehensive systematic review and meta-analyses to determine the effects of GLP-1 RA and SGLT2i drugs on IMT.

2. Methods

This systematic review is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [14]. The study protocol was registered with the International Prospective Registry of Systematic Reviews (PROSPERO).

2.1. Data Sources and Searching Strategy. To identify potentially relevant studies, searches were conducted in the following four databases (since inception to September 9, 2023): PubMed, EMBASE, Web of Science, and SCOPUS, with two reviewers (A.A. and S.H.) working independently and in parallel. Citations of all included studies and relevant published papers were reviewed by hand search. "Google Scholar" was also searched to find potentially relevant articles. Studies were found by searching for three main terms and their synonyms, including "IM," "SGLT2i," and "GLP-1 RA." The complete search strategy for each term is shown in Table S1. The search was not limited by time, type of article, or language. We used reference management software (EndNote X8) to import references, remove duplicates, and review the literature.

2.2. Selection Criteria. Inclusive criteria for this systematic review were studies that investigated IMT in groups of patients treated with GLP-1 RA or SGLT2i. Eligible studies that met the following criteria were included in the metaanalysis: (1) the studies reported mean IMT at baseline and final or mean change in IMT after GLP-1 RA or SGLT2i therapy, and (2) the follow-up period was at least 2 weeks. Two authors (A.A. and S.H.), working independently and in parallel, reviewed the abstract and included the paper reporting the effects of GLP-1 RA or SGLT2i on IMT. Subsequently, A.A. and S.H. independently assessed the full text of the papers and made the final decision. Disagreements in study selection were adjudicated by a third reviewer.

2.3. Quality Assessment. Two authors (L.H. and S.H.) independently assessed the quality of studies using the JBI checklists [15]. The JBI checklist assessed bias in selection, measurement, and analysis. If there were disagreements, they were resolved by discussion or referral to another investigator to achieve consensus. The checklist questions were answered "yes," "no," "unclear," or "not applicable." For each "yes" answer, 1 point is awarded, and after adding the points, the final score is calculated.

2.4. Data Extraction. The two investigators (A.A. and S.H.) independently extracted the following data: first name, year in which studies were conducted (if no data were provided, the year of study publication was considered), groups, dosage, population, size, gender, age, location, study design, follow-up, IMT at baseline, IMT at end, and disease duration.

2.5. Publication Bias and Statistical Analysis. Publication bias was examined using funnel plots, Egger's test, and Duval and Tweedie's trim and fill test. Pre- and postintervention IMT values were recorded to calculate the mean difference (MD) and 95% confidence interval (CI). Subgroup analyses were performed based on drug classes, and sensitivity analyses were performed based on effect models (random to fixed or vice versa), RTCs, T2DM patients, and R values (0.3, 0.5, and 0.8). The Cochrane Q statistic was used to assess heterogeneity, and if it was less than 0.05, a randomeffects model was used for analysis. Metaregression was performed to determine the correlation between IMT changes and disease duration, gender, follow-up period, and baseline IMT. A P value of less than 0.05 was considered statistically significant for the outcome and heterogeneity analyses. Data analysis was performed using Comprehensive Meta-Analysis software (CMA) V.3.

3. Results

The literature search yielded 708 related articles after duplicates were removed. Eighteen studies examined the effects of GLP-1 RA [11–13, 16–31], and eleven examined the effects of SGLT2i on IMT [32–42]. Studies that did not provide IMT results [43–49], duplicate data [50–56], combination therapies without apparent GLP-1 RA effects [57], or assessed IMT of arteries other than the carotid artery were excluded [58–60]. The study selection process is shown in Figure 1.

3.1. Characteristics of the Included Studies. Three different GLP-1 RA drugs were investigated in the included studies: liraglutide [11, 12, 16, 18, 23–29], semaglutide [21], and exenatide [19, 22, 30, 31]. Also, five different SGLT2i drugs were studied, including empagliflozin [32, 36, 38, 42], ipragliflozin [33, 39, 41], tofogliflozin [34, 40], dapagliflozin [35–37, 42], and luseogliflozin [40]. The range of intervention periods for GLP-1 RA trials ranged from 4 months [12, 13, 21, 26] to 3 years [29] and for SGLT2i trials was from 2 weeks [38] to 3.6 years [36]. All SGLT2i studies [32–42] and fifteen GLP-1 RA studies included T2DM patients [11, 12, 17, 19–27, 29–31]. Italy (n = 7) was the country with the largest number of published articles for GLP-1 RA and Japan for SGLT2i (n = 5). Characteristics of the evaluated studies are presented in Table 1.



FIGURE 1: PRISMA flow diagram of the systematic review process.

3.2. GLP-1 RA. Nineteen GLP-1 RA-treated groups with a total population of 790 subjects were included in the metaanalysis. Figure 2 shows that GLP-1 RA significantly reduced IMT (MD = -0.123, 95% CI (-0.170, -0.076), P < 0.0001, I^2 = 98%). A sensitivity analysis on studies that included only T2DM patients showed a higher potential of GLP-1 RA to reduce IMT (MD = -0.145, 95% CI (-0.196, -0.094), P < 0.0001, $I^2 = 98\%$) (Figure S1). In addition, a sensitivity analysis based on 5 RCTs reached the same conclusion (MD = -0.119, 95% CI (-0.219, -0.018), P = 0.021, $I^2 = 99\%$) (Figure 3). A subgroup analysis on liraglutide and exenatide trials significantly reduced IMT (liraglutide: MD = -0.127, 95% CI (-0.201, -0.054), $P = 0.001, I^2 = 99\%$; exenatide: MD = -0.144, 95% CI (-0.240, -0.047), P = 0.003, $I^2 = 99\%$) (Figure S2). Metaregression showed that IMT change was significantly correlated with baseline IMT (coefficient = -0.246, P = 0.0001) but not significantly correlated with duration of treatment, duration of diabetes, and gender (coefficient = -0.003, P = 0.635; coefficient = 0.009, P = 0.108; and coefficient = 0.001, P = 0.849, respectively) (Figure 4).

Meta-analysis of 4 studies (n = 343) showed a significant reduction in the GLP-1 RA group compared with the placebo/control group (MD = -0.398, 95% CI (-0.792, -0.004), P = 0.048, $I^2 = 68\%$) (Figure 5).

3.3. SGLT2i. Ten groups treated with SGLT2i with a total population of 879 subjects were included in the meta-

analysis. Figure 6 shows that SGLT2i could significantly reduce IMT (MD = -0.048, 95% CI (-0.092, -0.004), P = 0.031, $I^2 = 95\%$). In addition, a sensitivity analysis based on 4 RCTs reached the same conclusion (MD = -0.043, 95% CI (-0.119, 0.034), P = 0.274, $I^2 = 98\%$) (Figure 7), but the sensitivity analysis based on the change from random to fixed effects showed a significant reduction in IMT (MD = -0.067, 95% CI (-0.077, -0.057), P = 0.0001). A subgroup analysis on empagliflozin and tofogliflozin trials significantly reduced IMT (empagliflozin: MD = -0.066, 95%) CI (-0.094, -0.037), P < 0.0001, $I^2 = 0\%$; tofogliflozin: MD = -0.130, 95% CI (-0.145, -0.116), $P < 0.0001, I^2 = 0\%$), whereas ipragliflozin failed to reduce IMT (MD = -0.007, 95% CI (-0.019, 0.004), P = 0.222, $I^2 = 0\%$) (Figure S3). Metaregression showed that IMT change was not significantly correlated with baseline IMT, treatment gender duration. diabetes duration. and (coefficient = -0.092, P = 0.363; coefficient = -0.001, P =0.623; coefficient = -0.012, P = 0.178, and coefficient = -0.004, P = 0.171, respectively) (Figure 8).

All comparisons were repeated by changing the R value to 0.3, 0.5, or 0.8, but no differences were found. A sensitivity analysis in which the random-effects analysis was replaced by a fixed-effects analysis also confirmed the results, except as noted in the manuscript.

3.4. Quality Assessment and Publication Bias. Quality assessment using the JBI checklist and final scores for cohort

Study, year	Groups, dosage (per day)	Size, population	Male	Age (years)	Location	Study design	Follow- up	Baseline CIMT (mm)	Final CIMT (mm)	Disease duration (years)
<i>GLP-1 RA</i> Rizzo et al., 2012 [26]	Liraglutide 1.2 mg add on metformin 1500 mg	121 T2DM	59%	62 ± 9	Italy	Uncontrolled clinical trial	18 months	0.97 ± 0.18	0.78 ± 0.20	9 ± 8
Dejgaard et al., 2016 [16]	Liraglutide 1.8 mg Placebo	50 TIDM 50 TIDM	60% 70%	47 ± 13 49 ± 12	Denmark	Randomized, double-blinded clinical trial	24 weeks	ND	$\begin{array}{l} 0.01 \ (-0.01, \ 0.03) / \\ p = 0.361 \end{array}$	$\begin{array}{c} 20\pm12\\ 25\pm12 \end{array}$
Nikolic, 2021 [13]	Liraglutide 1.2 mg add on metformin	62 T2DM	50%	61 ± 9	Italy	Uncontrolled clinical trial	4 months	1.13 ± 0.29	0.92 ± 0.24	9 ± 8
Patti et al., 2019 [22]	Semaglutide 0.50 mg/week add on routine treatment	40 T2DM	65%	66 ± 10	Italy	Retrospective	4 months	1.04 ± 0.16	0.90 ± 0.14	14 ± 10
Giglio, 2014 [11]	Liraglutide add on metformin 1500-3000 mg	29 T2DM + NAFLD 29 T2DM	55% 55%	61 ± 10 61 ± 8	Italy	Clinical trial	8 months	1.00 ± 0.30 0.91 ± 0.23	0.90 ± 0.10 0.85 ± 0.15	$\begin{array}{c} 10\pm9\\9\pm8\end{array}$
Patti, 2023 [21]	Exenatide LAR 2 mg/week add on metformin 1500-3000 mg	60 T2DM	68%	60 ± 10	Italy	Uncontrolled clinical trial	8 months	0.98 ± 0.14	0.87 ± 0.15	9±8
Hopkins, 2013 [17]	Exenatide 20 µg Liraglutide 1.2 mg	9 T2DM + obesity 2 T2DM + obesity	63.6%	55 ± 8	United Kingdom	Uncontrolled clinical trial	6 months	0.76 ± 0.07	0.76 ± 0.11	8.3 ± 4.7
Kahal et al., 2015 [18]	Liraglutide 1.8 mg	13 PCOS 12 controls	%0	33.9 ± 6.7 33.5 ± 7.1	United Kingdom	Clinical trial	6 months	0.51 ± 0.05 0.48 ± 0.06	0.51 ± 0.05 0.48 ± 0.06	ND
Köseoğlu, 2021 [19]	Exenatide 20 μg	45 T2DM + obesity	8.8%	47.91 ± 7.30	Turkey	Uncontrolled clinical trial	6 months	1.04 ± 0.11	0.75 ± 0.12	ND
Zhang, 2022 [31]	Exenatide Insulin	27 T2DM 32 T2DM	70.0% 43.7%	58.85 ± 12.54 58.03 ± 13.32	China	Randomized, open- label clinical trial	52 weeks	ΟN	-0.1 0.02 (change from baseline)	6.59 ± 5.32 7.81 ± 6.02
Luna-Marco et al., 2023 [20]	GLP-1 RA Non-GLP-1 RA Control	59 T2DM 196 T2DM 175 Control	63% 55% 54%	56.5 ± 9.9 59.9 ± 10.5 54.9 ± 13.5	Spain	Cross-sectional	ŊŊ	ΟN	0.630 ± 0.742 0.750 ± 0.238 0.516 ± 0.070	13.8 ± 8.7 10.4 ± 8.1
Meng, 2023† [12]	Liraglutide Metformin and sulfonylurea	38 T2DM 40 T2DM	60.5% 45%	56 ± 11 59 ± 7	China	Randomized clinical trial	16 weeks	$\begin{array}{c} 1.14 \pm 0.10 \\ 1.13 \pm 0.13 \end{array}$	0.85 ± 0.08 1.05 ± 0.10	0.5 - 16.0 1.0 - 16.0
Patti et al., 2013 [23]	Liraglutide 1.2 mg add on metformin	64 T2DM	50%	63 ± 8	Italy	Uncontrolled clinical trial	8 months	1.19 ± 0.47	0.95 ± 0.21	9 ± 8

TABLE 1: Characteristics of included studies.

4

Study, year	Groups, dosage (per day)	Size, population	Male	Age (years)	Location	Study design	Follow- up	Baseline CIMT (mm)	Final CIMT (mm)	Disease duration (years)
Ripa, 2021 [24]	Liraglutide 1.8 mg Placebo	50 T2DM 48 T2DM	88.2% 80.4%	65.9 ± 8.6 66.9 ± 7.8	Denmark	Randomized, double-blinded clinical trial	26 weeks	0.77 ± 0.17 0.75 ± 0.14	0.76 ± 0.17 0.75 ± 0.14	12.2 ± 3.2 11.3 ± 3.4
Rizzo et al., 2012 [26]	Liraglutide 1.2 mg add on metformin 1500 mg	33 T2DM	58%	59 ± 9	Italy	Uncontrolled clinical trial	4 months	1.55 ± 0.45	1.36 ± 0.31	ND
Sun, 2023 [28]	Liraglutide 1.2 mg Lifestyle interventions	17 IGT + overweight 22 IGT + overweight	35.3% 31.9%	44.92 ± 14.69 48.91 ± 10.12	China	Randomized, double-blinded clinical trial	6 months	0.91 ± 0.25 0.91 ± 0.23	0.70 ± 0.16 0.92 ± 0.18	ND
Yoshida et al., 2018 [29]*‡	Liraglutide 0.9 mg Linagliptin	34 T2DM	23.5%	75.7 ± 7.8	Japan	Clinical trial	3 years	2.42 ± 1.65 2.25 ± 1.19	2.14 ± 1.40 2.19 ± 1.01	ND
Yoshida et al., 2012 [30]*	Exenatide $20 \mu g$ add on routine treatment Routine treatment	56 T2DM 50 T2DM	44.6% 44.6%	63.8 ± 11.0 63.8 ± 11.0	Japan	Clinical trial	12 months	1.09 ± 0.33 1.08 ± 0.27	1.02 ± 0.31 1.13 ± 0.34	ND
SGL T2i										
Irace et al., 2018 [32]	Empagliflozin Incretin-based therapy	40 T2DM 30 T2DM	75% 80%	58 ± 9 60 ± 7	Italy	Prospective cohort	3 months	0.831 ± 0.156 0.890 ± 0.146	0.766 ± 0.127 0.841 ± 0.109	$15\pm9\\17\pm10$
Kang, 2023 [33]	Ipragliflozin 50 mg Sitagliptin 100 mg	70 T2DM 70 T2DM	ND	ND	South Korea	Randomized, open- label clinical trial	24 weeks	0.900 ± 0.420 0.830 ± 0.230	0.900 ± 0.360 0.840 ± 0.250	ND
Katakami, 2022 [34]	Tofogliflozin 20 mg Conventional therapy	169 T2DM 171 T2DM	58.3% 58.0%	61.4 ± 9.3 60.8 ± 9.7	Multicenter (Japan)	Randomized, open- label clinical trial	104 weeks	0.870 ± 0.160 0.860 ± 0.150	0.740 ± 0.140 0.720 ± 0.130	12.1 ± 8.4 12.4 ± 8.2
Korzh et al., 2020 [35]*	Dapagliflozin 10 mg	35 T2DM	ND	ND	Ukraine	Clinical trial	12 weeks	ND	Decreased significantly from baseline	ΟN
Kourtidou, 2023 [36]	Empagliflozin/dapagliflozin Standard care	15 T2DM 25 T2DM	73.3% 68%	68.9 ± 7.3 73.2 ± 9.6	Greece	Cross-sectional	3.6 ± 1.2 years	QN	0.7 ± 0.2 0.9 ± 0.2 (no significant difference)	12.6 ± 9.1 13.3 ± 7.1
Lamaida, 2022* [37]	Dapagliflozin Standard care	20 T2DM 20 T2DM	ND	55 ± 10 50 ± 10	Italy	Clinical trial	2.0 years	ND	Decreased significantly from baseline	ŊŊ
Murakami and Mizuno, 2014 [38]*	SGLT2i Standard care	10 T2DM 10 T2DM	ND	ND	ND	Randomized clinical trial	2 weeks	0.340 ± 0.080 0.350 ± 0.080	0.310 ± 0.060 0.360 ± 0.050	ΟN

Journal of Diabetes Research

TABLE 1: Continued.

5

			1 AB	TE I: COUUIING					
Study, year	Groups, dosage (per day)	Size, Mal population	e Age (years)	Location	Study design	Follow- up	Baseline CIMT (mm)	Final CIMT (mm)	Disease duration (years)
Nomiyama et al., 2018 [39]	Ipragliflozin 50 mg	134 T2DM 52%	$6 53.9 \pm 10.5$	Japan	Clinical trial	52 weeks	0.760 ± 0.160	0.750 ± 0.150	8.2 ± 7.9
Sakai, 2019 [40]	Empagliflozin 10-25 mg Luseogliflozin 2.5-5 mg Tofogliflozin 20 mg	59 HfpEF + T2DM 61.5 63 HfpEF 42.9 + T2DM 78.6 62 HfpEF + T2DM	% 62.0±9.4 % 70.3±11.4 % 66.0±9.8	Japan	Clinical trial	12 weeks	$\begin{array}{c} 0.860 \pm 0.700 \\ 0.840 \pm 0.700 \\ 0.870 \pm 0.500 \end{array}$	0.780 ± 0.200 0.940 ± 0.400 0.730 ± 0.300	ŊŊ
Tanaka, 2023 [41]	Ipragliflozin 50 mg Standard care	241 T2DM 69.4 215 T2DM 67.2	% 67 (60, 72) % 68 (60, 73)	Multicenter (Japan)	Randomized, open- label clinical trial	24 months	0.8200 ± 0.037 0.8400 ± 0.037	0.815 ± 0.034 0.836 ± 0.039	9.1 ± 6.8 8.1 ± 6.9
Yamagishi et al., 2016 [42] *	SGLT2i	31 T2DM + obesity ND	53	Japan	Clinical trial	12 months	1.340 ± 0.480	1.220 ± 0.437	ND
*Conference papers. †C fatty liver disease; IGT:	hinese language. ‡Max MIT. Abbi impaired glucose tolerance; ND:	eviations: HfpEF: hea not determined.	rt failure with prese	erved ejection frac	tion; T2DM: type 2 diabe	etes mellitus;	PCOS: polycystic o	vary syndrome; NAFLI): nonalcoholic

TABLE 1: Continued.

Study name			Statistics for	or each s	udy				Differen	ice in means and 95% Cl			
	Difference in means	Standard error	Variance	Lower limit	Upper limit	Z-Value	p-Value				<u>Populatio</u> n	<u>Class</u>	Month
Rizzo, 2012, a	-0.190	0.011	0.000	-0.212	-0.168	-17.109	0.000		🖶	L	T2DM	Liraglutide	18
Dejgaard, 2016	0.010	0.010	0.000	-0.010	0.030	1.000	0.317			-	T1DM	Liraglutide	6
Nikolic, 2012	-0.210	0.022	0.000	-0.253	-0.167	-9.493	0.000				T2DM	Liraglutide	4
Patti, 2019	-0.140	0.015	0.000	-0.170	-0.110	-9.152	0.000			.	T2DM	Semaglutide	4
Giglio, 2012, NAFLI	0 -0.100	0.042	0.002	-0.183	-0.017	-2.362	0.018				T2DM/NAFLD	Liraglutide	8
Giglio, 2012	-0.060	0.026	0.001	-0.112	-0.008	-0.273	0.023				T2DM	Liraglutide	8
Patti, 2015	-0.110	0.012	0.000	-0.133	-0.087	-9.242	0.000				T2DM	Exenatide	8
Hopkins, 2012	0.000	0.021	0.000	-0.040	0.040	0.000	1.000				T2DM/Obesity	Exena/Lira	6
Kahal, 2015, PCOS	0.000	0.009	0.000	-0.017	0.017	0.000	1.000				PCOS	Liraglutide	6
Kahal, 2015	0.000	0.011	0.000	-0.021	0.021	0.000	1.000			#	Healthy	Liraglutide	6
Koseo?lu, 2015	-0.290	0.011	0.000	-0.311	-0.269	-26.522	0.000		- E -		T2DM/Obesity	Exenatide	6
Zhang, 2015	-0.100	0.004	0.000	-0.108	-0.092	-25.981	0.000				T2DM	Exenatide	12
Meng, 2021	-0.290	0.010	0.000	-0.309	-0.271	-29.795	0.000				T2DM	Liraglutide	4
Patti, 2013	-0.240	0.041	0.002	-0.320	-0.160	-5.867	0.000				T2DM	Liraglutide	8
Ripa, 2017	-0.010	0.015	0.000	-0.040	0.020	-0.658	0.511				T2DM	Liraglutide	6
Rizzo, 2012, b	-0.190	0.048	0.002	-0.284	-0.096	-3.975	0.000			-	T2DM	Liraglutide	4
Sun, 2009	-0.210	0.038	0.001	-0.284	-0.136	-5.577	0.000				IGT/Overweigh	t Liraglutide	6
Yoshida, 2018	-0.280	0.170	0.029	-0.614	0.054	-1.644	0.100	<			T2DM	Liraglutide	36
Yoshida, 2012	-0.070	0.027	0.001	-0.123	-0.017	-2.577	0.010				T2DM	Exenatide	12
	-0.123	0.024	0.001	-0.170	-0.076	-5.090	0.000						
								-0.50	-0.25	0.00	0.25		
									Favours A	Favours I	j.		

FIGURE 2: Forest plot displaying pre-post difference and 95% confidence interval for the impact of GLP-1 RA on IMT.



FIGURE 3: Forest plot displaying pre-post difference and 95% confidence interval for the impact of GLP-1 RA on IMT based on randomized clinical trials.

studies, cross-sectional studies, RCTs, and nonrandomized clinical trials are described in detail in Table S2. All funnel plots of all analyses are shown in the figures. Figure 9 shows the funnel plot of the pre-post comparison of GLP-1 RA and SGLT2i treatment, and Figure S4 shows the funnel plots of the sensitivity analysis. In addition, the results of the Egger test and the trim-and-fill method of Duval and Tweedie, which indicate no significant publication bias, are shown in Table 2 (Table 2).

4. Discussion

T2DM is associated with a high prevalence of cardiovascular risk, and pharmacotherapies have been introduced to reduce the risk of atherosclerosis in various ways, including glycemic control, lipid balance, uric acid lowering, and blood pressure control [61]. Our meta-analysis showed a significant reduction in IMT, a surrogate atherosclerosis marker, after GLP-1 RA or SGLT2i therapy; however, it appears that GLP-1 RA is more effective in reducing IMT. Similarly, a recent meta-analysis of RCTs showed that GLP-1 RAs were effective in preventing serious adverse cardiovascular events in T2DM patients with obesity (relative risk = 0.88, 95% CI (0.81, 0.96)), whereas SGLT2i marginally prevented serious adverse cardiovascular events (relative risk = 0.91, 95% CI

(0.83, 1.00)) [62]. In contrast to a recent review showing cardiovascular benefits for liraglutide and semaglutide but not for exenatide, we demonstrated that exenatide can also reduce IMT [63]. It appears that the effects of GLP-1 RA are not class-dependent, whereas the effects of SGLT2i are.

Consistent with our findings, previous studies reported that GLP-1 RA was effective in reducing major adverse events associated with cardiac events regardless of gender. In contrast, in terms of reducing major adverse events associated with cardiac events, SGLT2i was effective in men but not in women [64]. This inconsistency may be due to different outcome measures. Metaregression analysis showed that the effects of GLP-1 RA and SGLT2i persisted with longterm treatment, suggesting that these drugs do not induce tolerance. In contrast to a previous study claiming that the duration of T2DM might influence efficacy, the metaregression showed no significant correlation between the duration of diabetes and change in IMT [65]. However, the metaregression showed that higher baseline IMT leads to greater IMT reduction. A study by Kahal et al. showed that GLP-1 RA was not significantly effective in patients with polycystic ovary syndrome whose baseline IMT was lower than that of T2DM patients [18]. In these cases, confounding factors and heterogeneity may affect the results, so well-designed RCTs are warranted.



FIGURE 4: Meta-regression plots of the association between IMT with gender, follow-up, duration of diabetes, and baseline IMT for GLP-1 RA studies.



FIGURE 5: Forest plot displaying mean difference and 95% confidence interval for the impact of GLP-1 RA compared to control groups on IMT.



FIGURE 6: Forest plot displaying pre-post difference and 95% confidence interval for the impact of SGLT2i on IMT.



FIGURE 7: Forest plot displaying pre-post difference and 95% confidence interval for the impact of SGLT2i on IMT based on randomized clinical trials.



FIGURE 8: Metaregression plots of the association between IMT with gender, follow-up, duration of diabetes, and baseline IMT for SGLT2i studies.

A meta-analysis by Song et al. evaluated the efficacy of GLP-1-based therapies and concluded that IMT was not significantly reduced. Insufficient studies, heterogeneity, and pooling other GLP-1-based therapy other than GLP-1 RA including dipeptidyl peptidase-4 inhibitors may lead to different results compared with our findings [66]. They also showed that brain natriuretic peptide, a marker of atherosclerosis, decreased significantly with GLP-1-based therapies. Furthermore, in a prospective study of elderly people in Sweden, it was observed that higher serum GLP-1 levels correlated with lower IMT [67].

Prior studies suggest that liraglutide can regulate the NLRP3 inflammasome and NF- κ B signaling pathway, which

causes the inflammatory state [28, 68, 69]. It has also been shown that GLP-1 RA protects cardiomyocytes from IL 1β -induced metabolic dysfunction and mitochondrial dysfunction [70]. Previous studies have shown that GLP-1 RA therapy lowers both systolic and diastolic blood pressure [71], improves endothelial dysfunction [72, 73], and reduces macrophage foam cell formation and atherosclerosis [74]. Qu and Qu reviewed evidence from epidemiological and human studies that low-density lipoprotein cholesterol (LDL-C) is an important regulator in the development of atherosclerosis [75]. A previous meta-analysis by Zhao et al. showed a significant reduction in LDL-C following GLP-1 RA therapy [76], whereas Sánchez-García et al. did



FIGURE 9: Funnel plot displaying the impact of GLP-1 RA and SGLT2i on IMT.

TABLE 2:	Publication	bias of	evaluation	bv	Egger's	regression	test a	and D	uval a	and	Tweedie	trim	and	fill	test.
T T T T T T T T T T T T T T T T T T T	1 00110000001011	0100		~ .		100101011							~~~~~	****	
					()()										

Finding/distribution pattern	Egger's tes	st	Tr	im and fill method	
Finding/distribution pattern	Egger's intercept	P value	Number of trimmed studies	Point estimate after trim	Change after trim
Baseline-final GLP-1 RA	-1.191	0.706	1	-0.113	0.010
Baseline-final GLP-1 RA (RCTs)	-1.172	0.917	0	-0.119	0.000
Baseline-final GLP-1 RA (T2DM)	-1.685	0.565	0	-0.196	0.000
Baseline-final liraglutide	-2.523	0.590	0	-0.127	0.000
Baseline-final exenatide	-5.933	0.581	0	-0.240	0.000
GLP-1 RA compared to control	-6.759	0.085	0	-0.398	0.000
Baseline-final SGLT2i	0.621	0.816	0	-0.048	0.000
Baseline-final SGLT2i (RCTs)	5.190	0.629	0	-0.043	0.000

RCT: randomized clinical trial; T2DM: type 2 diabetes mellitus; GLP-1 RA: glucagon-like peptide-1 receptor agonists; SGLT2i: sodium-glucose cotransporter 2 inhibitors.

not achieve a significant reduction after SGLT2is [77]. Another mechanism described for GLP-1 RA agonists is that these drugs increase antioxidant enzymes (superoxide dismutase and glutathione reductase) and decrease reactive oxygen species and malondialdehyde levels [78]. In vivo studies have shown that GLP-1 RA reduces atherosclerosis by suppressing endoplasmic reticulum stress, macrophage apoptosis, and microvesicle production [79]. Hyperglycemia has also been shown to lead to a decrease in endothelial nitric oxide function via a decrease in synthesis and an increase in degradation and to play a role in endothelial dysfunction, with liraglutide effectively restoring endothelial nitric oxide synthase activity in the diabetic mouse model [80, 81]. The same mechanism involving amelioration of inflammation, insulin resistance, endothelial dysfunction, dislipidemia, hyperglycemia, and oxidative state has been proposed for SGLT2is [82-86]. Previous studies have demonstrated the importance of AT1R/NADPH oxidase/SGLT1 and 2 signaling pathways in promoting atherosclerosis

[87–89]. They showed that atherosclerotic plaques have higher SGLT2 expression [87–89]. A recent meta-analysis summarizing data from 9 RCTs and 2 cohorts concluded that SGLT2i improves flow-mediated dilation but not pulse wave velocity [90].

The paucity of high-quality randomized clinical trials in this systematic review is one of the major limitations of the current study. Lacking sufficient studies, we could not evaluate the effects of different classes, different doses, or patient characteristics of GLP-1 RA or SGLT2i on IMT. Also, there were insufficient studies to compare SGLT2i with control groups. There was too much heterogeneity, which could be due to different inclusion criteria, different types and dosages of GLP-1 RA or SGLT2i, follow-up time, and study design. Despite these aforementioned biases, sensitivity analyses yielded nearly consistent results.

In conclusion, GLP-1 RA and SGLT2i may reduce IMT. Among the different GLP-1 RAs, liraglutide was the most studied and had a significant effect on IMT reduction. In addition, GLP-1 RAs might be more effective than SGLT2is in lowering IMT.

Data Availability

Data is available on request from the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We thank the Student Research Committee of the Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran, and the cardiologists of Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran, for their scientific support.

Supplementary Materials

Table S1: search strategy of GLP-1 RA and SGLT2i. Table S2: quality assessment table for randomized clinical trial studies, cohort studies, cross-sectional studies, and nonrandomized studies based on JBI Critical Appraisal. Figure S1: GLP-1RA and IMT (sensitivity analysis on T2DM patients). Figure S2: liraglutide and exenatide effects on IMT. Figure S3: empagliflozin, tofogliflozin, and ipragliflozin effects on IMT. Figure S4: all analysis funnel plots (baseline-final comparison of GLP-1 RA (RCTs), baseline-final comparison of GLP-1 RA (T2DM), and baseline-final comparison of SGLT2i (RCTs)). (Supplementary Materials)

References

- E. Brown, J. P. H. Wilding, T. M. Barber, U. Alam, and D. J. Cuthbertson, "Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities," *Obesity Reviews*, vol. 20, no. 6, pp. 816–828, 2019.
- [2] H. Yaribeygi, M. Maleki, A. E. Butler, T. Jamialahmadi, and A. Sahebkar, "The impact of incretin-based medications on lipid metabolism," *Journal of Diabetes Research*, vol. 2021, Article ID 1815178, 10 pages, 2021.
- [3] H. Yaribeygi, M. Maleki, S. L. Atkin, T. Jamialahmadi, and A. Sahebkar, "Impact of incretin-based therapies on adipokines and adiponectin," *Journal of Diabetes Research*, vol. 2021, Article ID 3331865, 9 pages, 2021.
- [4] H. Yaribeygi, F. Lhaf, T. Sathyapalan, and A. Sahebkar, "Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: implications for lowering tissue damage," *Life Sciences*, vol. 231, article 116538, 2019.
- [5] S. Radbakhsh, T. Sathyapalan, M. Banach, and A. Sahebkar, "Incretins and microRNAs: interactions and physiological relevance," *Pharmacological Research*, vol. 153, article 104662, 2020.
- [6] M. Ashrafizadeh, H. Yaribeygi, S. L. Atkin, and A. Sahebkar, "Effects of newly introduced antidiabetic drugs on autophagy," *Diabetes & Metabolic Syndrome*, vol. 13, no. 4, pp. 2445–2449, 2019.

11

- [7] A. Akbari, M. Rafiee, T. Sathyapalan, and A. Sahebkar, "Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis," *Journal of Diabetes Research*, vol. 2022, Article ID 7520632, 17 pages, 2022.
- [8] H. Yaribeygi, S. L. Atkin, A. E. Butler, and A. Sahebkar, "Sodium-glucose cotransporter inhibitors and oxidative stress: an update," *Journal of Cellular Physiology*, vol. 234, no. 4, pp. 3231–3237, 2019.
- [9] H. Yaribeygi, S. L. Atkin, T. Jamialahmadi, and A. Sahebkar, "A review on the effects of new anti-diabetic drugs on platelet function," *Endocrine, Metabolic & Immune Disorders Drug Targets*, vol. 20, no. 3, pp. 328–334, 2020.
- [10] H. Yanai, H. Adachi, M. Hakoshima, and H. Katsuyama, "Glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors for atherosclerotic cardiovascular disease in patients with type 2 diabetes," *Cardiology Research*, vol. 14, no. 1, pp. 12–21, 2023.
- [11] R. V. Giglio, M. Rizzo, A. M. Patti et al., "Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study," *Diabetologia*, vol. 57, no. 1, p. S369, 2014.
- [12] X. M. Meng, Y. P. Hao, S. Yu, R. Z. Ren, X. Yu, and Y. X. Tang, "Effect of liraglutide on platelet distribution width and carotid intima-media thickness in type 2 diabetic mellitus patients with obesity," *Zhonghua Yi Xue Za Zhi*, vol. 103, no. 17, pp. 1316–1322, 2023.
- [13] D. Nikolic, R. V. Giglio, A. A. Rizvi et al., "Liraglutide reduces carotid intima-media thickness by reducing small dense lowdensity lipoproteins in a real-world setting of patients with type 2 diabetes: a novel anti-atherogenic effect," *Diabetes Therapy*, vol. 12, no. 1, pp. 261–274, 2021.
- [14] M. J. Page, J. E. McKenzie, P. M. Bossuyt et al., "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews," *Revista Espanola de Cardiologia*, vol. 74, no. 9, pp. 790–799, 2021.
- [15] L.-L. Ma, Y.-Y. Wang, Z.-H. Yang, D. Huang, H. Weng, and X.-T. Zeng, "Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?," *Military Medical Research*, vol. 7, no. 1, p. 7, 2020.
- [16] T. F. Dejgaard, N. B. Johansen, C. S. Frandsen et al., "Cardiovascular effects of liraglutide in patients with type 1 diabetes: a randomised, double-blinded placebo-controlled trial (Lira-1)," *Diabetologia*, vol. 59, no. 1, pp. S356–S357, 2016.
- [17] N. D. Hopkins, D. J. Cuthbertson, G. J. Kemp et al., "Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients," *Diabetes, Obesity & Metabolism*, vol. 15, no. 8, pp. 770–773, 2013.
- [18] H. Kahal, A. Aburima, T. Ungvari et al., "The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls," *BMC Endocrine Disorders*, vol. 15, no. 1, 2015.
- [19] D. Köseoğlu, S. S. Koparal, Ö. Ö. Başer, and D. Berker, "Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study," *Turkish Journal* of Medical Sciences, vol. 51, no. 1, pp. 167–174, 2021.
- [20] C. Luna-Marco, A. M. de Marañon, A. Hermo-Argibay et al., "Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium

interactions in type 2 diabetes," *Redox Biology*, vol. 66, article 102849, 2023.

- [21] A. M. Patti, R. V. Giglio, A. Allotta et al., "Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes," *Biomedicine*, vol. 11, no. 5, p. 1362, 2023.
- [22] A. M. Patti, D. Nikolic, A. Magan-Fernandez et al., "Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: an 8-month prospective study," *Diabetes Research and Clinical Practice*, vol. 149, pp. 163–169, 2019.
- [23] A. M. Patti, M. Rizzo, V. Di Bartolo et al., "Beneficial effects of liraglutide on carotid intima-media thickness in patients with type-2 diabetes: a 8-month prospective study," *Cardiology*, vol. 126, p. 290, 2013.
- [24] R. S. Ripa, E. H. Zobel, B. J. von Scholten et al., "Effect of Liraglutide on arterial inflammation assessed as [¹⁸F]FDG uptake in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial," *Circulation: Cardiovascular Imaging*, vol. 14, no. 7, article e012174, 2021.
- [25] M. Rizzo, M. Chandalia, A. M. Patti et al., "Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study," *Cardiovascular Diabetology*, vol. 13, no. 1, 2014.
- [26] M. Rizzo, A. M. Patti, V. Di Bartolo, R. V. Giglio, G. Montalto, and A. A. Rizvi, "Effect of liraglutide on carotid intima-media thickness in patients with type-2 diabetes: a 4-month prospective study," *Diabetes*, vol. 61, p. A109, 2012.
- [27] M. Rizzo, A. A. Rizvi, A. M. Patti et al., "Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study," *Cardiovascular Diabetology*, vol. 15, no. 1, p. 162, 2016.
- [28] L. Sun, Y. Yuan, Y. Li, and X. Rao, "Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: a double-blind, randomized controlled clinical trial," *Experimental and Therapeutic Medicine*, vol. 25, no. 6, p. 249, 2023.
- [29] M. Yoshida, T. Morimoto, E. Oh et al., "Possibility of liraglutide for prevention of dementia progression in patients with type 2 diabetes," *Diabetes*, vol. 67, Supplement_1, p. A296, 2018.
- [30] M. Yoshida, N. Yamamoto, A. Saeki et al., "Exenatide therapy reduced intina-media thickness of carotid artery in patients with type 2 diabetes," *Diabetologia*, vol. 55, pp. S322–S323, 2012.
- [31] J. Zhang, T.-Z. Xian, M.-X. Wu et al., "Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial," *Journal of Investigative Medicine*, vol. 70, no. 7, pp. 1529–1535, 2022.
- [32] C. Irace, F. Casciaro, F. B. Scavelli et al., "Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy," *Cardiovascular Diabetology*, vol. 17, no. 1, p. 52, 2018.
- [33] S. M. Kang, H. M. Yun, M. Sohn, and S. Lim, "Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study," *Diabetes, Obesity and Metabolism*, vol. 25, no. 7, pp. 1922–1931, 2023.
- [34] N. Katakami, T. Mita, N. Maeda et al., "Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid

wall—a sub-analysis of the UTOPIA trial," *Cardiovascular Diabetology*, vol. 21, no. 1, p. 19, 2022.

- [35] O. Korzh, A. Titkova, and S. Krasnokutskiy, "Dapagliflozin improves endothelial function and microvascular reactivity in type 2 diabetes mellitus," *American Heart Journal*, vol. 229, p. 168, 2020.
- [36] C. Kourtidou, V. Rafailidis, G. Varouktsi et al., "Effects of sodium-glucose co-transporter-2 inhibitors on markers of vascular damage," *Journal of Personalized Medicine*, vol. 13, no. 3, p. 536, 2023.
- [37] N. Lamaida and A. Cerciello, "Dapaglifozin and intimamediatickness in type II diabetic patients," *European Heart Journal Supplements*, vol. 24, p. K144, 2022.
- [38] T. Murakami and S. Mizuno, "Abstract 13577: A Selective SGLT2 Inhibitor Early Resolutes Metabolic and Arterial Disturbances in Type-2 Diabetics With Coronary Artery Disease," *Circulation*, vol. 130, article A13577, Supplement_2, 2014.
- [39] T. Nomiyama, D. Shimono, T. Horikawa et al., "Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka study of ipragliflozin (FUSION)," *Endocrine Journal*, vol. 65, no. 8, pp. 859–867, 2018.
- [40] T. Sakai and S. Miura, "Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction-novel prospective cohort study," *Circulation Reports*, vol. 1, no. 7, pp. 286–295, 2019.
- [41] A. Tanaka, M. Sata, Y. Okada et al., "Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial," *European Heart Journal - Cardiovascular Pharmacotherapy*, vol. 9, no. 2, pp. 165–172, 2023.
- [42] T. Yamagishi, H. Hasegawa, and H. Kanai, "[PP.05.19] Effects of SGLT2 inhibitors on blood pressure, BAPWV, carotid arterial IMT and elastic modulus in type 2 diabetic patients with obesity," *Journal of Hypertension*, vol. 34, article e145, Supplement 2, 2016.
- [43] N. D'Onofrio, C. Sardu, M. C. Trotta et al., "Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose cotransporter2 inhibitor treatment," *Molecular Metabolism*, vol. 54, article 101337, 2021.
- [44] T. Sakai and S. Miura, "Effect of sodium-glucose cotransporter 2 inhibitor on vascular endothelial function and diastolic function in patients with heart failure with preserved ejection fraction (HFpEF)," *European Heart Journal Cardiovascular Imaging*, vol. 18, article iii222, 2017.
- [45] A. C. Sposito, I. Breder, A. A. S. Soares et al., "Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial," *Cardiovascular Diabetology*, vol. 20, no. 1, p. 74, 2021.
- [46] J. Zhang, T. Xian, M. Wu et al., "Effects of exenatide and insulin aspart 30 on vascular function in diabetic patients with different baseline characteristics," *Chinese Journal of Diabetes Mellitus*, vol. 13, no. 2, pp. 156–161, 2021.
- [47] A. Maloberti, E. Cimino, M. Casati et al., "PP.05.27: arterial structural and functional effects of incretin therapy in type 2 diabetes mellitus patients: preliminary results," *Journal of Hypertension*, vol. 33, Supplement 1, pp. e175–e176, 2015.

- [48] I. K. B. Rasmussen, E. H. Zobel, R. S. Ripa et al., "Liraglutide reduces cardiac adipose tissue in type 2 diabetes: a secondary analysis of the LIRAFLAME randomized placebo-controlled trial," *Diabetes, Obesity and Metabolism*, vol. 23, no. 12, pp. 2651–2659, 2021.
- [49] W. Ren, J. Guo, J. Liu, and G. Xi, "Effect of liraglutide on cardiovascular markers in type 2 diabetes mellitus," *Diabetes*, vol. 64, p. A339, 2015.
- [50] M. Barone, A. Cutruzzolà, M. Parise et al., "Empagliflozin influences hemorheology, arterial morphology AD function," *Giornale Italiano di Cardiologia*, vol. 20, no. 12, p. 128S, 2019.
- [51] N. Lamaida, E. De Luca, M. Cutolo, and A. Cerciello, "P190 carotid doppler ultrasonographic and dapaglifozin in type 2 diabetic patient," *European Heart Journal Supplements*, vol. 24, article C126, Supplement_C, 2022.
- [52] N. Al Busaidi, A. A. Rizvi, G. Montalto et al., "Liraglutide improves metabolic parameters and reduces carotid intimamedia thickness in patients with type 2 diabetes: a 2-year prospective study," *Diabetes*, vol. 64, pp. A289–A290, 2015.
- [53] R. Chianetta, A. M. Patti, G. Castellino et al., "Exenatide LAR reduces subclinical carotid atherosclerosis and improves endothelial function in patients with type 2 diabetes: an 8-month prospective study, diabetes," *Stoffwechsel und Herz*, vol. 26, no. 6, p. 356, 2017.
- [54] A. Adamo, R. Chianetta, R. V. Giglio et al., "Liraglutide improves metabolic parameters and reduces intima-media thickness in obese vs. non-obese patients with type 2 diabetes: 18-month prospective study," *Diabetes, Stoffwechsel und Herz*, vol. 26, no. 6, pp. 356-357, 2017.
- [55] D. Nikolic, A. M. Patti, R. V. Giglio et al., "Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes: a real-world 18month prospective study," *Diabetes Therapy*, vol. 13, no. 3, pp. 453–464, 2022.
- [56] M. Rizzo, A. Ferlita, D. Nikolic et al., "Effects of liraglutide on metabolic parameters and carotid intima-media thickness in patients with the metabolic syndrome: a 12-month prospective pilot study," *Diabetes*, vol. 63, p. A261, 2014.
- [57] M. Abdul-Ghani, C. L. Puckett, C. L. Triplitt et al., "Durable HbA1c reduction with initial combination therapy with metformin/pioglitazone/exenatide in subjects with new-onset diabetes-six-year follow-up of the edict study," *Diabetes*, vol. 67, Supplement_1, pp. A32–A33, 2018.
- [58] T. Murakami, K. Ohsato, and K. Niwa, "Dapagliflozin provides multiple ultrasonic-evaluated antiatherosclerotic effects independent of diabetic improvement for type-2 diabetics with coronary artery disease receiving statin or sartan," *Circulation*, vol. 134, 2016.
- [59] T. Murakami and K. Ohsato, "Long-term antidiabetic treatment by dapagliflozin provides multiple antiatherosclerotic effects independent of diabetic improvement for type-2 diabetics with coronary artery disease receiving statin or sartan," *Circulation*, vol. 140, 2019.
- [60] C. Sardu, M. C. Trotta, F. C. Sasso et al., "SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis," *Cardiovascular Diabetology*, vol. 22, no. 1, p. 80, 2023.
- [61] A. Akbari, M. Razmi, M. Rafiee, G. F. Watts, and A. Sahebkar, "The effect of statin therapy on serum uric acid levels: a systematic review and meta-analysis," *Current Medicinal Chemistry*, vol. 31, no. 13, pp. 1726–1739, 2024.

- [62] K. Uneda, Y. Kawai, T. Yamada et al., "Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients," *Scientific Reports*, vol. 11, no. 1, p. 10166, 2021.
- [63] A. Sachinidis, D. Nikolic, A. P. Stoian et al., "Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors," *Metabolism*, vol. 111, p. 154343, 2020.
- [64] A. K. Singh and R. Singh, "Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials," *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, vol. 14, no. 3, pp. 181– 187, 2020.
- [65] L. Blonde, R. Pencek, and L. MacConell, "Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes," *Cardiovascular Diabetology*, vol. 14, no. 1, p. 12, 2015.
- [66] X. Song, H. Jia, Y. Jiang et al., "Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes mellitus: a meta-analysis," *Scientific Reports*, vol. 5, no. 1, article 10202, 2015.
- [67] A. Jujić, P. M. Nilsson, N. Atabaki-Pasdar et al., "Glucosedependent insulinotropic peptide in the high-normal range is associated with increased carotid intima-media thickness," *Diabetes Care*, vol. 44, no. 1, pp. 224–230, 2021.
- [68] A. Shiraki, J.-i. Oyama, H. Komoda et al., "The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells," *Atherosclerosis*, vol. 221, no. 2, pp. 375–382, 2012.
- [69] J. Xia, Q. Li, Y. Liu et al., "A GLP-1 analog liraglutide reduces intimal hyperplasia after coronary stent implantation via regulation of glycemic variability and NLRP3 inflammasome/IL-10 signaling in diabetic swine," *Frontiers in Pharmacology*, vol. 11, p. 372, 2020.
- [70] L. Zhang, J. Tian, S. Diao, G. Zhang, M. Xiao, and D. Chang, "GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction," *Chemico-Biological Interactions*, vol. 332, p. 109252, 2020.
- [71] L. E. Robinson, T. A. Holt, K. Rees, H. S. Randeva, and J. P. O'Hare, "Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis," *BMJ Open*, vol. 3, no. 1, article e001986, 2013.
- [72] T. Nyström, M. K. Gutniak, Q. Zhang et al., "Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease," *American Journal of Physiology-Endocrinology and Metabolism*, vol. 287, no. 6, pp. E1209–E1215, 2004.
- [73] A. Ceriello, K. Esposito, R. Testa, A. R. Bonfigli, M. Marra, and D. Giugliano, "The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes," *Diabetes Care*, vol. 34, no. 3, pp. 697–702, 2011.
- [74] Y. Tashiro, K. Sato, T. Watanabe et al., "A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis," *Peptides*, vol. 54, pp. 19–26, 2014.

- [75] B. Qu and T. Qu, "Causes of changes in carotid intima-media thickness: a literature review," *Cardiovascular Ultrasound*, vol. 13, no. 1, p. 46, 2015.
- [76] Y. Zhao, W. Zhao, H. Bu, M. Toshiyoshi, and Y. Zhao, "Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: a systematic review and meta-analysis of 16 RCTs," *Medicine*, vol. 102, no. 6, article e32892, 2023.
- [77] A. Sánchez-García, M. Simental-Mendía, J. M. Millán-Alanís, and L. E. Simental-Mendía, "Effect of sodium-glucose cotransporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials," *Pharmacological Research*, vol. 160, p. 105068, 2020.
- [78] Ł. Bułdak, K. Łabuzek, R. J. Bułdak, G. Machnik, A. Bołdys, and B. Okopień, "Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages," *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 388, no. 9, pp. 905–919, 2015.
- [79] J. Li, X. Liu, Q. Fang, M. Ding, and C. Li, "Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats," *Diabetology* & Metabolic Syndrome, vol. 9, no. 1, p. 94, 2017.
- [80] A. Aljada and P. Dandona, "Effect of insulin on human aortic endothelial nitric oxide synthase," *Metabolism*, vol. 49, no. 2, pp. 147–150, 2000.
- [81] S. J. Zhou, L. Bai, L. Lv et al., "Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway," *Molecular Medicine Reports*, vol. 10, no. 5, pp. 2587–2594, 2014.
- [82] J. H. Han, T. J. Oh, G. Lee et al., "The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE-/- mice fed a western diet," *Diabetologia*, vol. 60, no. 2, pp. 364–376, 2017.
- [83] J. Pennig, P. Scherrer, M. C. Gissler et al., "Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice," *Scientific Reports*, vol. 9, no. 1, p. 17937, 2019.
- [84] B. Ganbaatar, D. Fukuda, M. Shinohara et al., "Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice," *European Journal of Pharmacology*, vol. 875, p. 173040, 2020.
- [85] D. Z. Khat and M. Husain, "Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA," *Current Diabetes Reports*, vol. 18, no. 7, p. 45, 2018.
- [86] S. H. Park, M. A. Farooq, S. Gaertner et al., "Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat," *Cardiovascular Diabetology*, vol. 19, no. 1, p. 19, 2020.
- [87] S. H. Park, E. Belcastro, H. Hasan et al., "Angiotensin IIinduced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins," *Cardiovascular Diabetology*, vol. 20, no. 1, p. 65, 2021.
- [88] Z. Liu, X. Ma, I. Ilyas et al., "Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics," *Theranostics*, vol. 11, no. 9, pp. 4502–4515, 2021.
- [89] A. S. Alshnbari, S. A. Millar, S. E. O'Sullivan, and I. Idris, "Effect of sodium-glucose cotransporter-2 inhibitors on endo-

thelial function: a systematic review of preclinical studies," *Diabetes Therapy*, vol. 11, no. 9, pp. 1947–1963, 2020.

[90] R. Wei, W. Wang, Q. Pan, and L. Guo, "Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials," *Frontiers in Endocrinology*, vol. 13, article 826604, 2022.